Page 3 - Devanshu Singla

Why a 70:30 gold-silver mix works best for investors, explains Pratik Oswal

Investors are increasingly using index funds as long-term wealth-creation vehicles rather than for short tactical exposure, Oswal said

ICICI Prudential AMC IPO opens: Analysts suggest long-term buy; here's why

ICICI Prudential AMC IPO: Analysts at Canara Bank Securities and Anand Rathi have recommended subscribing to the issue from a long-term perspective

Park Medi World vs Nephrocare Health IPO: Where should you park your money?

Analysts broadly have a positive view of Park Medi World, given the strong outlook for India's healthcare delivery market and the company's expansion strategy

Meesho lists at 46% premium; analysts upbeat on long-term view; here's why

Choice Equity Broking has initiated coverage on Meesho with a 'Buy' rating, citing the company's structural competitive Moats, strong monetisation runway, and accelerating path to profitability

Park Medi World IPO: Analysts split on prospects; should you apply?

The three-day subscription window to bid for the Park Medi World IPO will close on Friday, December 12, 2025

Ambit starts coverage on Tata Motors CV with 19% upside target; here's why

Ambit expects TMCV's revenue and Ebitda to grow at a CAGR of 6 per cent and 7 per cent over FY25-28, respectively, on the back of high-margin and non-core revenues

Sensex falls 800 pts, Nifty below 26k: Why are stock markets falling today?

The BSE Sensex tumbled 803 points in the intraday to hit a low of 84,909, and the NSE Nifty50 also slipped below the 26,000 mark in the intraday to hit a low of 25,902.95

Corona Remedies IPO opens Dec 8: Bid or skip? Here's what experts suggest

Corona Remedies IPO Date: The unlisted shares of Corona Remedies were trading at ₹1,427, commanding a grey market premium of ₹365 or 34.4 per cent on Friday

JM Financial starts coverage on KPR Mill with 'Buy'; check target price

JM Financial has set a target price of ₹1,215 per share, implying an upside potential of 21 per cent

Largecaps to outperform in 2026 as SMID valuations look stretched: BofA Sec

Bank of America (BofA) Securities said it continues to prefer largecaps over small and midcaps (SMIDs) in CY26 as valuations remain elevated and risks are skewed to the downside

Largecaps to outperform in 2026 as SMID valuations look stretched: BofA

Bank of America (BofA) Securities said it continues to prefer largecaps over small and midcaps (SMIDs) in CY26 as valuations remain elevated and risks are skewed to the downside

Largecaps to outperform in 2026 as SMID valuations look stretched: BofA

Bank of America (BofA) Securities said it continues to prefer largecaps over small and midcaps (SMIDs) in CY26 as valuations remain elevated and risks are skewed to the downside

Largecaps to outperform in 2026 as SMID valuations look stretched: BofA

Bank of America (BofA) Securities said it continues to prefer largecaps over small and midcaps (SMIDs) in CY26 as valuations remain elevated and risks are skewed to the downside

Meesho IPO booked 3x on strong demand; should you bid too? Analysts weigh

Analysts highlight Meesho's zero-commission, asset-light business model, coupled with its multi-sided marketplace and logistics network

Wakefit IPO: D2C growth story, key risks ahead, what investors should know

According to the RHP, Wakefit's performance is heavily dependent on its "Wakefit" brand, under which it sells mattresses, furniture and home furnishings

Meesho vs Aequs vs Vidya Wires IPO: Which one should you bet on?

Analysts remain largely positive on Meesho IPO and Vidya Wires IPO, citing strong growth prospects and operational efficiency, while views on Aequs IPO are cautious

Vidya Wires IPO opens tomorrow: Bid or skip? Here's what experts suggest

The unlisted shares of Vidya Wires were trading at ₹57, commanding a grey market premium of ₹5 or 9.6 per cent on Tuesday

Meesho IPO opens Dec 3: Analysts recommend long-term buy; should you bid?

Analysts at SBI Securities and Arihant Capital have recommended that investors subscribe to the Meesho IPO with a long-term perspective.

Aequs IPO opens Dec 3: Know key strengths, risks before you invest

Aequs IPO will be offered at a price band of ₹118 to ₹124 per share and a lot size of 120 shares

Meesho IPO to unlock ₹1,020 crore bonanza for founders, early backers

Meesho has set the price band for its IPO in the range of ₹105 to ₹111 per cent, valuing it around ₹50,095.75 crore